RenalytixAI To Validate KidneyIntelX™ In Collaboration With University Medical Center Groningen

Pixabay License | Source:  ID 905513 , no changes made.
Advertisement img

Renalytix AI plc, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, has announced a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500 patients with Type II Diabetes. The study will assess how effectively KidneyIntelX identifies patients with fast-progressing kidney disease who would be most likely to benefit from new drug therapies to prevent or slow down their progression to end-stage renal disease and dialysis.

Renalytix AI, founded in 2018, leveraging the Mount Sinai Health System BioMe™ BioBank repository, in New York City, is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally, with an estimated $114 billion cost of chronic and end-stage kidney disease to the United States healthcare system alone. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Founded in 1797, discovery at the UMCG is characterised by a combination of fundamental and patient orientated clinical research. The interaction between these two stimulates the development of new clinical and research opportunities. The UMCG focuses on healthy ageing and personalized medicine in all priority areas: research, clinical care and education.

Featured Partners

RenalytixAI expects to commercially launch KidneyIntelX as a laboratory developed test in its CLIA laboratory facilities in the United States later this year. As part of the planned evaluation, the KidneyIntelX test will be performed at multiple time points on over 9,000 patient samples from completed clinical trial biobanks, providing valuable insight into the potential utility of KidneyIntelX as a predictor of response to breakthrough therapies for the treatment of diabetic kidney disease.

“The ability of KidneyIntelX to discriminate fast-progressing kidney disease offers pharma the potential to enrich clinical trials with patients most likely to benefit most from novel drug therapies. Additionally, the potential to predict drug response in these patients is critically important to directing clinical use of new therapies.” – Hiddo J.L. Heerspink, Pharm.D., Department of Clinical Pharmacy and Pharmacology, UMCG and lead investigator in the planned evaluation